Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model

Following on from ezutromid, the first-in-class benzoxazole utrophin modulator that progressed to Phase 2 clinical trials for the treatment of Duchenne muscular dystrophy, a new chemotype was designed to optimise its physicochemical and ADME profile. Herein we report the synthesis of SMT022357, a se...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Tetrahedron
Main Authors: Babbs, Arran, Berg, Adam, Chatzopoulou, Maria, Davies, Kay E., Davies, Stephen G., Edwards, Benjamin, Elsey, David J., Emer, Enrico, Figuccia, Aude L.A., Fletcher, Ai M., Guiraud, Simon, Harriman, Shawn, Moir, Lee, Robinson, Neil, Rowley, Jessica A., Russell, Angela J., Squire, Sarah E., Thomson, James E., Tinsley, Jonathon M., Wilson, Francis X., Wynne, Graham M.
Formato: Artigo
Idioma:Inglês
Publicado em: Pergamon Press 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7369641/
https://ncbi.nlm.nih.gov/pubmed/32713969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tet.2019.130819
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados